Paclitaxel vs Epidoxorubicin plus Paclitaxel as Second-Line Therapy for Platinum-Refractory and -Resistant Ovarian Cancer
Articolo
Data di Pubblicazione:
1999
Citazione:
Paclitaxel vs Epidoxorubicin plus Paclitaxel as Second-Line Therapy
for Platinum-Refractory and -Resistant Ovarian Cancer / G. Bolis, F. Parazzini, G. Scarfone, A. Villa, M. Amoroso, E. Rabaiotti, A. Polatti, S. Reina, E. Pirletti. - In: GYNECOLOGIC ONCOLOGY. - ISSN 0090-8258. - 72:1(1999 Jan), pp. 60-64. [10.1006/gyno.1998.5237]
Abstract:
We conducted a randomized clinical trial to compare the efficacy
and safety of paclitaxel and a combination including paclitaxel
and epidoxorubicin as second-line treatment in platinumrefractory
or -resistant ovarian cancer. Patients who had
progressive or stable disease during first-line therapy with regimens
containing cisplatin or carboplatin (platinum-refractory patients)
or who responded and subsequently relapsed within 6
months after discontinuation of first-line platinum-based regimen
(platinum-resistant patients) were eligible for the study. They were
randomly allocated to paclitaxel 175 mg/m2 every 28 days (41
women) for five cycles or epidoxorubicin 120 mg/m2 iv plus paclitaxel
150 mg/m2 iv every 28 days (40 women). The overall
response rates (complete plus partial response) were, respectively,
17.1% in the paclitaxel and 34.2% in the epidoxorubicin plus
paclitaxel group (P 5 0.10). The 2-year percentage survival was 18
in the paclitaxel group and 10 in the epidoxorubicin plus paclitaxel
group. A higher frequency of leukopenia and thrombocytopenia
was reported in women allocated to epidoxorubicin plus paclitaxel
than in the paclitaxel alone group, but the frequency of neurotoxicity
was higher in the paclitaxel alone group. An important
limitation of the study is the small sample size. With this sample
size we can exclude that multiagent therapy in comparison with
single-agent therapy improves response in platinum-refractory
and -resistant ovarian cancer of more than 25%.
Tipologia IRIS:
01 - Articolo su periodico
Elenco autori:
G. Bolis, F. Parazzini, G. Scarfone, A. Villa, M. Amoroso, E. Rabaiotti, A. Polatti, S. Reina, E. Pirletti
Link alla scheda completa: